Questions presented
SCOTUS records, cert granted 2 Nov 2005
- Whether liability can be imposed for willfully inducing patent infringement under 35 U.S.C. § 271(b) based solely on evidence that a party has disseminated a basic scientific fact to others.
- Whether an express limitation in a patent claim can be ignored so as to allow the patent to cover the exact opposite of what was claimed.
- Whether a method patent setting forth an indefinite, undescribed, and non-enabling step directing a party simply to "correlat[e]" test results can validly claim a monopoly over a basic scientific relationship used in medical treatment such that any doctor necessarily infringes the patent merely by thinking about the. relationship after looking at a test result.
Opinion summary
Etalia.ai summary of the majority opinion
The case Laboratory Corporation of America Holdings, DBA LabCorp v. Metabolite Laboratories, Inc., et al., 2005 revolved around a patent dispute. Metabolite sued LabCorp for infringement of its patent which covered both a method for determining levels of homocysteine (an amino acid) in the body and correlating those levels with deficiencies in certain B vitamins. The Supreme Court initially agreed to hear the case but later dismissed it as improvidently granted without providing any reasons or judgment on merits. However, Justice Breyer dissented from this dismissal arguing that the patent was invalid because natural phenomena (like correlations between homocysteine and vitamin deficiency) cannot be patented under U.S law.
Dissent summary
Etalia.ai summary of the dissenting opinions
In the dissenting opinion for Laboratory Corporation of America Holdings v. Metabolite Laboratories, Inc., Justice Breyer argued that the patent in question should not have been granted because it covered a basic scientific relationship used in medical treatment decisions and thus violated principles of patent law. He contended that allowing such patents would inhibit future innovation rather than promote it as intended by the Constitution's Patent Clause. The justice expressed concern about potential negative impacts on public health if companies could monopolize basic, natural biological relationships through patents. Furthermore, he criticized the majority for dismissing LabCorp's appeal on procedural grounds instead of addressing these significant issues related to patentability and their implications for medical practice and research.
Opinion of the Court
Decided 22 Jun 2006 · Official report
Oral argument transcript
Argued 21 Mar 2006